Table 1. The participants’ clinical characteristics based on lung disease status.

	MAC-LD n=56	MAC contamination n=11	M. kansasii-LD n=14	RGM-LD** n=26	PTB n=48	TB contacts n=42
Age (years)	67.8 [16.0]	60.9 [18.5]	56.9 [17.4]*	67.0 [13.3]	60.9 [17.9]*	50.1 [18.5]*
Male gender	28 (50%)	7 (64%)	11 (79%)	16 (62%)	32 (67%)	13 (31%)
Disease duration (months)	13.2 [21.8]	-	2.9 [8.2]*	4.3 [7.5]*	1.3 [1.1]*	-
Underlying co-morbidity	18 (32%)	4 (36%)	3 (21%)	9 (35%)	23 (48%)	5 (12%)*
Diabetes mellitus	4 (7%)	1 (9%)	1 (7%)	3 (12%)	7 (15%)	3 (7%)
Malignancy***	7 (13%)	1 (9%)	1 (7%)	2 (8%)	9 (19%)	2 (5%)
Hemodialysis	0	1 (9%)*	0	2 (8%)*	3 (6%)	0
Autoimmune diseases****	5 (9%)	0	1 (7%)	0	2 (4%)	0*
Liver cirrhosis	2 (4%)	1 (9%)	0	2 (8%)	8 (17%)*	0
Past TB history	8 (14%)	2 (18%)	4 (29%)	1 (4%)	0*	0*
MAC GPL antibody, U/mL	4.27 [6.32]	0.45 [0.73]*	0.16 [0.15]*	1.11 [2.27]*	0.78 [2.47]*	0.28 [0.74]*
Leukocytes, per µL	6926 [2743]	7045 [2225]	9063 [5082]	7528 [3628]	7661 [3658]	-
Hemoglobin, g/dL	12.6 [2.1]	12.6 [2.5]	12.2 [2.3]	12.2 [2.2]	12.7 [2.0]	-

Abbreviations: GPL, glycopeptidolipid; LD, lung disease; MAC, Mycobacterium avium complex; NTM, non-tuberculous mycobacteria; PTB, pulmonary tuberculosis; RGM, rapidly-growing mycobacteria

Data are no. (%) or mean [standard deviation]

^* p<0.05 between the indicated group and the MAC-LD group

^**RGM includes 14 M. abscessus, 7 M. fortuitum, and 5 M. chelonae

^***Malignancy includes 5 lung cancer, 4 head and neck cancer, 3 leukemia, 3 hepatoma, 2 breast cancer, 2 bladder cancer, 2 biliary tract cancer, and 1 thyroid cancer

Autoimmune diseases includes 3 rheumatoid arthritis, and each one of systemic lupus erythematosus, ankylosing spondilytis, Sjögren syndrome, Graves' disease, and autoimmune related nephrotic syndrome